Literature DB >> 9815754

Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas.

S Ménard1, G Tomasic, P Casalini, A Balsari, S Pilotti, N Cascinelli, B Salvadori, M I Colnaghi, F Rilke.   

Abstract

Infiltration by lymphoid cells is a common feature of many human tumors, including breast carcinomas, and the degree of infiltration has been suggested to be a measure of the host immune response. Our analyses in a series of 1919 cases of primary ductal and lobular infiltrating breast carcinomas from women with a long-term follow-up revealed: (a) a 16-17% frequency of infiltrated tumors independent of the patient's age at diagnosis; and (b) a strong positive correlation between survival rates and the presence of lymphocytes at the tumor site in patients less than 40 years of age (P = 0.0002) but no association with prognosis in patients 40 years of age or older. Multivariate analysis indicated that lymphoid infiltration is independent of other conventional prognostic factors such as nodal status and tumor size in predicting survival. Thus, a possible immune response against the tumor seems to be relevant only in women with early-onset tumors. Because the immune system is functionally maximum in younger years, declining with age, this finding might reflect a difference in the efficiency of the immune system. Alternatively, the biology of these tumors might differ, leading to a difference in immuno-genicity.

Entities:  

Mesh:

Year:  1997        PMID: 9815754

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  40 in total

Review 1.  Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity.

Authors:  Caroline Jochems; Jeffrey Schlom
Journal:  Exp Biol Med (Maywood)       Date:  2011-04-12

2.  High IL-17-positive tumor immune cell infiltration is indicative for chemosensitivity of ovarian carcinoma.

Authors:  Raoul A Droeser; Uwe Güth; Serenella Eppenberger-Castori; Sylvia Stadlmann; Christian Hirt; Luigi Terracciano; Gad Singer
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-28       Impact factor: 4.553

3.  CXCR3 deficiency enhances tumor progression by promoting macrophage M2 polarization in a murine breast cancer model.

Authors:  Steve Oghumu; Sanjay Varikuti; Cesar Terrazas; Dmitri Kotov; Mohd W Nasser; Catherine A Powell; Ramesh K Ganju; Abhay R Satoskar
Journal:  Immunology       Date:  2014-09       Impact factor: 7.397

4.  Leukocyte composition of human breast cancer.

Authors:  Brian Ruffell; Alfred Au; Hope S Rugo; Laura J Esserman; E Shelley Hwang; Lisa M Coussens
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-08       Impact factor: 11.205

Review 5.  Stromal biomarkers in breast cancer development and progression.

Authors:  Jenny A Rudnick; Charlotte Kuperwasser
Journal:  Clin Exp Metastasis       Date:  2012-06-10       Impact factor: 5.150

6.  Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting.

Authors:  Luisa Carbognin; Sara Pilotto; Rolando Nortilli; Matteo Brunelli; Alessia Nottegar; Isabella Sperduti; Diana Giannarelli; Emilio Bria; Giampaolo Tortora
Journal:  Oncologist       Date:  2016-02-10

7.  CCL2 -2518 A/G single nucleotide polymorphism as a risk factor for breast cancer.

Authors:  Lukasz Kruszyna; Margarita Lianeri; Błażej Rubis; Hanna Knuła; Maria Rybczyńska; Sylwia Grodecka-Gazdecka; Paweł P Jagodziński
Journal:  Mol Biol Rep       Date:  2010-06-20       Impact factor: 2.316

Review 8.  Tumor vaccines for breast cancer.

Authors:  Karen S Anderson
Journal:  Cancer Invest       Date:  2009-05       Impact factor: 2.176

9.  High level of chromosomal aberration in ovarian cancer genome correlates with poor clinical outcome.

Authors:  Leslie Cope; Ren-Chin Wu; Ie-Ming Shih; Tian-Li Wang
Journal:  Gynecol Oncol       Date:  2012-11-28       Impact factor: 5.482

Review 10.  Breast cancer stem cells, pathways and therapeutic perspectives 2011.

Authors:  Anjana Nigam
Journal:  Indian J Surg       Date:  2012-06-24       Impact factor: 0.656

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.